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Introduction
Globally, tuberculosis (TB) is the ninth leading cause of mortality 
with an estimated 1.6 million deaths reported in 20161. South 
Africa has one of the world’s highest burdens of TB with 
an estimated incidence of 438 000 cases in 20162. The “End 
TB Strategy” aims to reduce global TB incidence by 90% 
and TB-related deaths by 80% by 20301.
In 2011, the World Health Organization (WHO) recommended 
the GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA, 
USA), a TB polymerase chain reaction (PCR) based test as the 
initial investigation of choice in patients with human immu-
nodeficiency virus (HIV) co-infection or presumed multidrug 
resistant (MDR) TB3. Despite the introduction of this widely 
available test with a rapid turnaround time into the South 
African public sector in 2011, TB remains notoriously 
difficult to diagnose, for reasons including suboptimal adher-
ence to national diagnostic algorithms and challenges related to 
patient follow-up4,5.
Few data exist to guide the use of Xpert MTB/Rif on broncho-
alveolar lavage (BAL) specimens. Xpert MTB/RIF has been 
evaluated in BAL specimens from individuals with presumed 
TB who are sputum scarce or smear negative and has been 
shown to outperform smear microscopy in both high and low 
TB burden regions6–9. The South African national TB guidelines 
do not specify whether BAL specimens should be processed 
similarly to sputum for the Xpert MTB/RIF test, how many 
specimens should be tested, whether the specimens should 
be centrifuged prior to processing, or how results should 
be interpreted in cases of non-concordance with other TB 
diagnostic tests10.
In our public-sector based pulmonology clinic in urban South 
Africa, diagnostic bronchoscopy is used to evaluate medically 
complex patients for a variety of respiratory presentations occur-
ring in the background of high rates of HIV and TB endemicity11. 
In this context, mycobacterial smear and Mycobacterium 
tuberculosis (M.tb) culture are routinely performed on all diag-
nostic BAL specimens. In 2014, the use of Xpert MTB/RIF was 
approved for use on non-sputum samples at our facility. During 
this same period, a second Xpert MTB/RIF test was performed 
on most BAL samples obtained at our facility by the African 
Health Research Institute (AHRI) as part of an ongoing research 
study. Access to two Xpert MTB/RIF results performed on 
pooled BAL fluid sample at two independent laboratories 
provided a unique opportunity to evaluate the diagnostic yield 




Inkosi Albert Luthuli Central Hospital is a quaternary hospi-
tal in Durban, KwaZulu-Natal (KZN), South Africa. It is one 
of two hospitals in the public sector providing subspecialist 
services for the province. Patients with suspected infection 
(including TB), inflammatory lung disease or lung malignancy 
are referred to the Department of Pulmonology for flexible 
bronchoscopy and bronchoalveolar lavage (BAL) for diagnos-
tic purposes. The diagnosis or exclusion of TB is an important 
aspect to the clinical management of these patients. Bacterial, 
mycobacterial and fungal smear and culture are performed 
routinely on all BAL specimens whilst cytology and tests for 
Pneumocystis jerovicii are performed only when clinically 
indicated. Since 2014, Xpert MTB/Rif has been performed 
routinely on all BAL specimens. Since 2013, patients undergo-
ing diagnostic bronchoscopy at the facility have been offered 
enrollment in a research protocol, “Bronchoalveolar lavage 
fluid collection for the study of Mycobacterium tuberculosis 
immunology” (BE037/12).
Study population
We retrospectively audited a database of all participants 
(≥18 years of age) who consented to participate in the above- 
mentioned study and had adequate return of bronchoalveolar 
lavage fluid for analysis between July 2014 and June 2016. Patients 
with at least one Xpert MTB/RIF result and a TB culture result 
were included.
Bronchoscopy procedure
Standard bronchoscopy procedure was performed with appro-
priate sedation, monitoring of vital signs and clinician 
assessment regarding procedure safety12. Accompanying chest 
radiography or computed tomography (CT) scans dictated the lung 
segment that was sampled. Two hundred millilitres of sterile saline 
was infused into the lung segment in 20 ml aliquots, with the 
lavage fluid pooled into a sterile container.
Microbiological Tests
Bronchoalveolar fluid was sent for laboratory testing, includ-
ing Xpert MTB/RIF [Catalogue number CGXMTB/RIF-50] 
(1 mL) and TB culture (5 mL in liquid culture medium for eval-
uation. The TB culture specimen was decontaminated with 
sodium hydroxide (1%), sodium citrate and PH 6.8 phos-
phate buffer, then added to the Mycobacteria Growth Indica-
tor Tube (MGIT) [Catalogue number 245122], containing 4ml 
Middlebrook 7H9 broth liquid medium supplied by Becton 
Dickson. An antibiotic mixture (0.8ml) comprising Polymyxin B 
(6000 µg), Amphotericin B (600 µg), Nalidixic acid (2400 µg), 
Trimethoprim (600 µg) and Azlocillin (600 µg; PANTA; 
BBL MGIT PANTA Antibiotic mixture; BD)[Catalogue 
number 245124] was added and the specimen and innoculated 
into the BACTEC MGIT 960 system (Becton Dickson, Franklin 
Lakes, NJ, USA)[Catalogue number 445870]. A second Xpert 
MTB/RIF specimen (1 mL) was sent to the independent 
research laboratory. Both laboratories performed parallel test-
ing of aliquots of the pooled samples using version 4.3 of 
the Xpert MTB/RIF assay according to the manufacturer 
specified protocol13.
Consensus diagnosis of pulmonary disease at the time of 
bronchoscopy
A panel of three clinicians (a general physician [DFK], an infec-
tious disease specialist [EBW] and a pulmonologist [MS]) 
retrospectively analyzed each case utilizing all available clini-
cal data (clinical history, physical examination, radiology, 
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other laboratory and microbiology results, histopathology, results 
of all TB diagnostic tests, and data associated with follow-up 
visits). The panel determined the consensus diagnosis that best 
explained each participant’s lung disease.
Participants were categorized as having a consensus diagno-
sis of tuberculosis if they had active pulmonary tuberculosis at 
the time of bronchoscopy, whether or not additional underlying 
lung pathology was present. Participants with a consensus diag-
nosis of tuberculosis were classified according to the updated 
WHO TB case definition as “bacteriologically confirmed” 
if there was any positive biological specimen (AFB smear 
microscopy, TB culture, or Xpert MTB/RIF) or “clinically diag-
nosed” if the TB microbiological tests were negative and the 
diagnosis was made based on other evidence (e.g., histology, 
response to anti-tuberculosis treatment)14.
Ethical considerations
All patients provided informed consent to participate in the 
research protocol, which was approved by the University of 
KwaZulu-Natal Biomedical Research Ethics Committee 
(BE610/16), the Partners Institutional Review Board and the 
KwaZulu-Natal Department of Health (KZ_2016RP53_969). 
Patients were allocated sequential numerical identity numbers, 
which are not medical identifiers.
Statistics
Sensitivity and specificity for each test was calculated using the 
clinical consensus diagnosis as the gold standard, using cross-
tabulation. All data was analysed using SPSS software (SPSS 
25.0, Armonk NY: IBM Corp). Extracted data is available 
as underlying data15.
Results
Cohort characteristics and consensus diagnosis
In total, 101 patients were enrolled in the parent study between 
July 2014 and June 2016; of these 98 had a BAL TB culture result 
and at least one BAL Xpert MTB/RIF result and were included 
in the final analysis (Figure 1). The median age of the study 
participants was 48 years (interquartile range 19-80 years) and 
51% of the subjects were female. Of these, 19 participants had a 
consensus diagnosis of tuberculosis at the time of bronchoscopy 
(19%). A consensus diagnosis that did not include active tuber-
culosis was indicated for 79 participants (81%); of these, the 
leading diagnoses were: no identified infectious/inflammatory/ 
neoplastic lung disease, interstitial lung disease associated 
with connective tissue disease, lung cancer, sarcoidosis and 
bronchiectasis (Figure 2).
Immunosuppression prevalence was high. Of the overall cohort, 
26% (25 participants) were HIV infected with 84% of those on 
antiretroviral therapy. Additionally, 29% were actively receiv-
ing immunosuppressive medication for connective tissue 
disease or sarcoidosis. Four percent were actively using or had 
recently received chemotherapy for solid organ or haematological 
malignancy.
Rates of previous episodes of tuberculosis were high overall 
(33%) and equally balanced between participants with current 
TB and in participants who did not have a current episode of 
Figure 1. Study flow diagram showing the patients included in the analysis and proportion of patients with positive and negative 
bronchoalveolar lavage (BAL) tuberculosis microbiologic results.
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Figure 2. Clinical diagnosis (%) of the 98 patients enrolled in the study: Participants were categorized as having a consensus 
diagnosis of tuberculosis if they had active pulmonary tuberculosis at the time of bronchoscopy, whether or not additional underlying 
lung pathology was present. *Interstitial lung disease not due to connective tissue disease i.e Idiopathic pulmonary fibrosis, Non-specific 
interstitial pneumonia COPD – chronic obstructive pulmonary disease.
active TB (32% and 33% of each group respectively) by clinical 
consensus diagnosis.
Performance of TB diagnostic tests against the consensus 
clinical diagnosis
Of the 19 participants with a consensus diagnosis of tubercu-
losis, 14 (74%) had bacteriologically proven TB (Table 1). M.tb 
culture provided the basis for bacteriologic diagnosis of TB 
in nine (47%) of these cases, two thirds (7/9) of which were 
also supported by at least one positive Xpert MTB/RIF test. In 
the 10 cases with negative M.tb culture, at least one positive 
Xpert MTB/RIF test provided the basis for bacteriologic diag-
nosis in five of the cases. Five cases (26%) had a clinical 
consensus diagnosis of TB with all bacteriologic tests negative. 
Compared to the diagnostic yield of M.tb culture alone (47%), 
the addition of one Xpert MTB/RIF test increased the yield 
by two cases (11%), with a second Xpert/RIF adding three 
additional cases (16%).
Against the clinical consensus diagnosis, the sensitivity and 
specificity of M.tb culture alone was 47% and 100%, the 
pooled sensitivity and specificity of Xpert MTB/RIF was 
45% and 99% and the sensitivity and specificity of all bacte-
riological tests compared to the clinical consensus diagnosis was 
68% and 97% respectively.
Of the 19 cases with a clinical consensus diagnosis of TB, 12 
(63%) had at least one negative BAL Xpert MTB/RIF result-
ing in a high false negative rate of 55%. Low bacillary load 
appeared to be a factor as 11 of these 12 cases (92%) were 
acid fast bacilli (AFB) negative on smear microscopy of the 
alveolar fluid.
There was one false positive BAL Xpert MTB/RIF result (1%) 
in our cohort. This case was determined to be due to laboratory 
error as the leftover sample was retested (due to low clinical 
suspicion of TB) and produced consistently negative results.
Discrepancy between parallel Xpert MTB/Rif tests
Of the 98 patients enrolled, 63 participants (64%) had two BAL 
Xpert MTB/RIF results. Of those, 58 (92%) were concordant 
and five (8%) were discordant. Four of the discordant test pairs 
occurred in patients with a clinical consensus diagnosis 
of TB.
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Discussion
In this medically complex cohort of patients with high rates 
of HIV-infection and comorbidities necessitating therapeutic 
immunosuppression, TB was the single leading cause of lung 
disease at the time of bronchoscopy.
Despite intensive investigations including, in most cases, 
multiple Xpert MTB/RIF tests on bronchoalveolar lavage fluid, 
26% of cases determined to have active tuberculosis by clinical 
consensus had no microbiological evidence for TB and less than 
half of the TB cases (47%) had a positive BAL TB culture. Per-
forming Xpert MTB/RIF testing on bronchoalveolar lavage fluid 
increased the yield of bacteriologically proven TB cases and the 
yield was further increased by performing two independent tests.
In our cohort, the pooled sensitivity of Xpert MTB/RIF test-
ing of BAL fluid compared to consensus diagnosis (45%) was 
lower than in other published reports from high-burden TB 
settings6,7,9,16. This is likely due to differences in the nature of 
our cohort as TB was not the primary diagnostic consideration 
for most of the participants we evaluated. Our findings are 
comparable to those of le Palud et al who evaluated the accu-
racy of Xpert MTB/RIF against a composite reference standard 
in 162 patients undergoing flexible bronchoscopy for presumed 
TB in a low TB burden country7. They found Xpert MTB/RIF 
sensitivity to be 60% against the composite reference standard7.
Most of the participants in our cohort who had a clinical diag-
nosis of TB had negative BAL AFB smears, low rates of M.tb 
culture positivity and high rates of conditions associated with 
paucibacillary disease including HIV-infection, connective tissue 
disease and/or therapeutic immunosuppression. Patients with 
extrapulmonary TB or HIV and TB co-infection who have 
culture negative TB are reported to have a lower bacillary load 
in the lungs attributed to poor cavity formation17–19 and lower 
likelihood of Xpert MTB/RIF positivity16. We suspect that 
these factors contributed to the poor sensitivity of TB micro-
biological tests and specifically Xpert MTB/RIF in our 
cohort. In addition to factors associated with paucibacillary 
disease, differences in lung sampling and sample dilution can 
Table 1. Analysis of Pulmonary tuberculosis cases classified according to the WHO TB case 
definitions: Patients grouped (A–C) based on strength and concordance of TB microbiologic tests.
TB diagnostic tests in 19 patients with Tuberculosis 
(All tests performed on bronchoalveolar lavage unless otherwise specified)
PID number TB Culture Xpert MTB/Rif 1 Xpert MTB/Rif 2 Other diagnostic test
Group A: TB culture positive
1020 + + ND
1025 + + ND
1036 + + ND
1060 + + +
1084 + + +
1026 + + -
1030 + - ND
1059 + - -
1057 -* - -
Group B: TB culture negative with at least one positive Xpert MTB/Rif
1007 - + ND
1016 - + ND
1047 - - +
1072 - - +
1093 - - +
Group C: TB culture and Xpert MTB/Rif negative
1032 - - - Histology: AFB + on open lung biopsy
1055 - - - Miliary pattern on CXR
1002 - - ND
1005 - - ND
1028 - - ND
ND: Not done, AFB: Acid fast bacilli, CXR: Chest X-Ray. * Sputum culture positive one week prior to bronchoscopy.
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lower TB bacillary load in BAL fluid compared to expectorated 
sputum16.
We found that multiple Xpert MTB/RIF testing on broncho-
alveolar lavage fluid increased the yield of bacteriologically 
proven TB, consistent with the results of Boehme and col-
leagues, who conducted a multicenter study and found that testing 
multiple sputum samples with Xpert MTB/RIF had a modest 
benefit over a single test. In smear negative but culture 
confirmed TB, the sensitivity of Xpert MTB/RIF was 72% for 
one test, 85% for two tests and 90.2% for three tests20. In con-
trast, Theron et al evaluated 154 patients with presumed TB, 
with two Xpert MTB/RIF assays on BAL fluid specimens 
(centrifuged and uncentrifuged) and found that centrifugation 
of a second Xpert MTB/RIF did not alter test sensitivity 
against TB culture9.
In our cohort, the addition of a second Xpert MTB/RIF test 
resulted in a modest increase in non-concordance (8% of the 
63 cases with two Xpert MTB/RIF tests) and of these, a signifi-
cant proportion (80%) were deemed to be a true positive paired 
with a false negative result. We had a low BAL Xpert MTB/RIF 
false positive rate (1%). This did not significantly impact the test 
specificity and is comparable with results from other studies7,9,16.
Limitations
Patients evaluated at our hospital were medically complex 
and reflect a referral bias, making comparisons with other 
studies on Xpert MTB/RIF use in BAL fluid difficult. The use 
of two laboratories may have contributed to the discordance 
through procedural variability, despite the use of manufac-
turer specified methods. Finally, the numbers of participants 
with specific patterns of non-concordant TB test results were 
insufficient for specific analyses of causes contributing to the 
discordance.
Conclusions
Our study shows that in a medically complex group of patients 
from a high HIV and TB endemic setting, TB remains the lead-
ing cause of lung disease but a significant proportion of patients 
have paucibacillary disease lowering the sensitivity of M.tb diag-
nostic tests. In this setting, negative TB diagnostic tests should 
be interpreted with caution. We urge clinicians to consider 
submitting additional Xpert MTB/RIF tests in patients with a 
clinical suspicion of TB as we have shown an improved yield of 
11% with a single Xpert MTB/RIF and a further 16% with a 
second Xpert MTB/RIF assay. We recommend that when con-
ducting a diagnostic evaluation of such patients, BAL testing 
should be augmented by sending additional specimens that 
may further increase diagnostic yield. Submission of expecto-
rated or induced sputum or pooled endotracheal aspirate alongside 
BAL fluid has the potential to improve diagnostic yield 
(Box 1). Additional research to improve the sensitivity of TB 
diagnostics in medically complex patients is urgently needed.
We acknowledge that for most clinicians working in the pub-
lic sector in resource-constrained environments, access to CT 
scans and specialized procedures such as bronchoscopy or 
surgical lung biopsies may be unavailable, but we emphasize 
the importance of maintaining a high suspicion for tuberculo-
sis and implementing good clinical judgment, even in the face 
of negative Xpert MTB/RIF tests. Many patients will need to be 
treated empirically for TB, but should receive vigilant 
follow-up to monitor for response to treatment.
Box 1. Summary of the factors to consider when ordering 
and interpreting TB diagnostic tests
Factors to consider:
•    Patient characteristics: HIV status, immunosuppression 
(including the use of immunosuppressive drugs), 
previous tuberculosis (TB) and exposure to anti-
tuberculous therapy
•    Disease characteristics: Paucibacillary disease
•    Sampling factors: Expectorated sputum vs 
bronchoalveolar lavage fluid
Recommendations:
•    Attempt to obtain expectorated sputum samples or 
pooled endotracheal aspirates at bronchoscopy
•    Submit two Xpert MTB/Rif tests
•    When results are discordant, a positive result should be 
favoured and treatment for TB commenced
•    Interpret negative TB diagnostic tests with caution in a 





This project contains the following underlying data:
•    FakeyKhan_dataset.xlsx (Participant age, HIV status, 
Previous TB history, current TB details, medical co- 
morbidities, Results of Xpert MTB/RIF test on BAL 
from 1. Research unit and 2. IALCH, BAL TB culture result, 
Other diagnostic test results of importance, final consensus 
clinical diagnosis)
•    FakeyKhan_datadictionary.xlsx (Format and description 
of variables included in FakeyKhan_dataset.xlsx)
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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